Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
AACR 2025 preview – distressed biotechs seek redemption
Ikena, Senti and others look to clinical presentations at AACR.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
ALX flunks its gastric test
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
